Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas

Elin Hardell, Sofia Josefson, Mehran Ghaderi, Tone Skeie-Jensen, Sofia Westbom-Fremer, Elizabeth H. Cheek, Debra Bell, Jonas Selling, J. Kenneth Schoolmeester, Anna Måsbäck, Ben Davidson, Joseph W. Carlson

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Undifferentiated uterine sarcomas (UUS) are a heterogenous group of high-grade mesenchymal tumors. Although these tumors are highly aggressive, a subset of patients may experience long-term survival. These tumors have previously been divided morphologically into uniform and pleomorphic types. A previous study demonstrated that a mitotic index cutoff of 25 mitoses/10 high-power fields (corresponding to 11.16 mitotic figures/mm 2) could successfully divide tumors into 2 prognostic groups with significantly different overall survival. The goals of the current study were to (1) validate this mitotic index cutoff in an independent, multicenter cohort and (2) explore the prognostic value of the mitotic index groups in relation to other clinicopathologic variables. Cases were included from 3 independent institutions: The Norwegian Radium Hospital, The Mayo Clinic, and Skåne University Hospital. A total of 40 tumors were included after central review. All cases were negative for the YWHAE-FAM22A/B and JAZF1-JJAZ1 translocations. Survival data were available on all patients. In this study, one-third of patients with UUS survived beyond 5 years. The crude (unadjusted) Cox Proportional Hazards model revealed a number of parameters that significantly impacted overall survival, including mitotic index group, patient age, stage, and the presence of tumor necrosis. Classification into the uniform and pleomorphic types was not prognostic. Combining these parameters into an adjusted model revealed that only the mitotic index group and stage were prognostic. On the basis of these findings, it is proposed that UUS be subdivided into "mitogenic" and "not otherwise specified" types.

Original languageEnglish (US)
Pages (from-to)1231-1237
Number of pages7
JournalAmerican Journal of Surgical Pathology
Volume41
Issue number9
DOIs
StatePublished - Jan 1 2017

Fingerprint

Mitotic Index
Sarcoma
Neoplasms
Survival
Radium
Proportional Hazards Models
Mitosis
Necrosis
Age Groups

Keywords

  • endometrial stromal tumors
  • mitotic index
  • survival
  • undifferentiated uterine sarcoma

ASJC Scopus subject areas

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine

Cite this

Hardell, E., Josefson, S., Ghaderi, M., Skeie-Jensen, T., Westbom-Fremer, S., Cheek, E. H., ... Carlson, J. W. (2017). Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas. American Journal of Surgical Pathology, 41(9), 1231-1237. https://doi.org/10.1097/PAS.0000000000000894

Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas. / Hardell, Elin; Josefson, Sofia; Ghaderi, Mehran; Skeie-Jensen, Tone; Westbom-Fremer, Sofia; Cheek, Elizabeth H.; Bell, Debra; Selling, Jonas; Schoolmeester, J. Kenneth; Måsbäck, Anna; Davidson, Ben; Carlson, Joseph W.

In: American Journal of Surgical Pathology, Vol. 41, No. 9, 01.01.2017, p. 1231-1237.

Research output: Contribution to journalArticle

Hardell, E, Josefson, S, Ghaderi, M, Skeie-Jensen, T, Westbom-Fremer, S, Cheek, EH, Bell, D, Selling, J, Schoolmeester, JK, Måsbäck, A, Davidson, B & Carlson, JW 2017, 'Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas', American Journal of Surgical Pathology, vol. 41, no. 9, pp. 1231-1237. https://doi.org/10.1097/PAS.0000000000000894
Hardell, Elin ; Josefson, Sofia ; Ghaderi, Mehran ; Skeie-Jensen, Tone ; Westbom-Fremer, Sofia ; Cheek, Elizabeth H. ; Bell, Debra ; Selling, Jonas ; Schoolmeester, J. Kenneth ; Måsbäck, Anna ; Davidson, Ben ; Carlson, Joseph W. / Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas. In: American Journal of Surgical Pathology. 2017 ; Vol. 41, No. 9. pp. 1231-1237.
@article{4f5d89398ca042ffab4cdbf451861b2b,
title = "Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas",
abstract = "Undifferentiated uterine sarcomas (UUS) are a heterogenous group of high-grade mesenchymal tumors. Although these tumors are highly aggressive, a subset of patients may experience long-term survival. These tumors have previously been divided morphologically into uniform and pleomorphic types. A previous study demonstrated that a mitotic index cutoff of 25 mitoses/10 high-power fields (corresponding to 11.16 mitotic figures/mm 2) could successfully divide tumors into 2 prognostic groups with significantly different overall survival. The goals of the current study were to (1) validate this mitotic index cutoff in an independent, multicenter cohort and (2) explore the prognostic value of the mitotic index groups in relation to other clinicopathologic variables. Cases were included from 3 independent institutions: The Norwegian Radium Hospital, The Mayo Clinic, and Sk{\aa}ne University Hospital. A total of 40 tumors were included after central review. All cases were negative for the YWHAE-FAM22A/B and JAZF1-JJAZ1 translocations. Survival data were available on all patients. In this study, one-third of patients with UUS survived beyond 5 years. The crude (unadjusted) Cox Proportional Hazards model revealed a number of parameters that significantly impacted overall survival, including mitotic index group, patient age, stage, and the presence of tumor necrosis. Classification into the uniform and pleomorphic types was not prognostic. Combining these parameters into an adjusted model revealed that only the mitotic index group and stage were prognostic. On the basis of these findings, it is proposed that UUS be subdivided into {"}mitogenic{"} and {"}not otherwise specified{"} types.",
keywords = "endometrial stromal tumors, mitotic index, survival, undifferentiated uterine sarcoma",
author = "Elin Hardell and Sofia Josefson and Mehran Ghaderi and Tone Skeie-Jensen and Sofia Westbom-Fremer and Cheek, {Elizabeth H.} and Debra Bell and Jonas Selling and Schoolmeester, {J. Kenneth} and Anna M{\aa}sb{\"a}ck and Ben Davidson and Carlson, {Joseph W.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/PAS.0000000000000894",
language = "English (US)",
volume = "41",
pages = "1231--1237",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas

AU - Hardell, Elin

AU - Josefson, Sofia

AU - Ghaderi, Mehran

AU - Skeie-Jensen, Tone

AU - Westbom-Fremer, Sofia

AU - Cheek, Elizabeth H.

AU - Bell, Debra

AU - Selling, Jonas

AU - Schoolmeester, J. Kenneth

AU - Måsbäck, Anna

AU - Davidson, Ben

AU - Carlson, Joseph W.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Undifferentiated uterine sarcomas (UUS) are a heterogenous group of high-grade mesenchymal tumors. Although these tumors are highly aggressive, a subset of patients may experience long-term survival. These tumors have previously been divided morphologically into uniform and pleomorphic types. A previous study demonstrated that a mitotic index cutoff of 25 mitoses/10 high-power fields (corresponding to 11.16 mitotic figures/mm 2) could successfully divide tumors into 2 prognostic groups with significantly different overall survival. The goals of the current study were to (1) validate this mitotic index cutoff in an independent, multicenter cohort and (2) explore the prognostic value of the mitotic index groups in relation to other clinicopathologic variables. Cases were included from 3 independent institutions: The Norwegian Radium Hospital, The Mayo Clinic, and Skåne University Hospital. A total of 40 tumors were included after central review. All cases were negative for the YWHAE-FAM22A/B and JAZF1-JJAZ1 translocations. Survival data were available on all patients. In this study, one-third of patients with UUS survived beyond 5 years. The crude (unadjusted) Cox Proportional Hazards model revealed a number of parameters that significantly impacted overall survival, including mitotic index group, patient age, stage, and the presence of tumor necrosis. Classification into the uniform and pleomorphic types was not prognostic. Combining these parameters into an adjusted model revealed that only the mitotic index group and stage were prognostic. On the basis of these findings, it is proposed that UUS be subdivided into "mitogenic" and "not otherwise specified" types.

AB - Undifferentiated uterine sarcomas (UUS) are a heterogenous group of high-grade mesenchymal tumors. Although these tumors are highly aggressive, a subset of patients may experience long-term survival. These tumors have previously been divided morphologically into uniform and pleomorphic types. A previous study demonstrated that a mitotic index cutoff of 25 mitoses/10 high-power fields (corresponding to 11.16 mitotic figures/mm 2) could successfully divide tumors into 2 prognostic groups with significantly different overall survival. The goals of the current study were to (1) validate this mitotic index cutoff in an independent, multicenter cohort and (2) explore the prognostic value of the mitotic index groups in relation to other clinicopathologic variables. Cases were included from 3 independent institutions: The Norwegian Radium Hospital, The Mayo Clinic, and Skåne University Hospital. A total of 40 tumors were included after central review. All cases were negative for the YWHAE-FAM22A/B and JAZF1-JJAZ1 translocations. Survival data were available on all patients. In this study, one-third of patients with UUS survived beyond 5 years. The crude (unadjusted) Cox Proportional Hazards model revealed a number of parameters that significantly impacted overall survival, including mitotic index group, patient age, stage, and the presence of tumor necrosis. Classification into the uniform and pleomorphic types was not prognostic. Combining these parameters into an adjusted model revealed that only the mitotic index group and stage were prognostic. On the basis of these findings, it is proposed that UUS be subdivided into "mitogenic" and "not otherwise specified" types.

KW - endometrial stromal tumors

KW - mitotic index

KW - survival

KW - undifferentiated uterine sarcoma

UR - http://www.scopus.com/inward/record.url?scp=85020493265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020493265&partnerID=8YFLogxK

U2 - 10.1097/PAS.0000000000000894

DO - 10.1097/PAS.0000000000000894

M3 - Article

C2 - 28622181

AN - SCOPUS:85020493265

VL - 41

SP - 1231

EP - 1237

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 9

ER -